EXECUTIVE INTERVIEWS

  • CDMO-To-Hospital: A Direct Ending For Generic Shortages?
    CDMO-To-Hospital: A Direct Ending For Generic Shortages?

    Part 2 of our look at the unique business model and ambitious plans of Civica Rx.

  • Strategies For Success: Developing Drugs For Orphan Diseases
    Strategies For Success: Developing Drugs For Orphan Diseases

    Drug development, in general, is a challenging feat. When it comes to orphan drugs, however, those challenges are compounded. As more orphan drugs are developed, pharma companies can tap into some of the successful strategies that have worked previously.

  • How Serial Entrepreneur Robert Hariri Is Revolutionizing Cell Therapy
    How Serial Entrepreneur Robert Hariri Is Revolutionizing Cell Therapy

    Robert Hariri, M.D., Ph.D., is an engineer, a jet aviator, a movie producer, a professor and a surgeon. However, it’s his experience as a biomedical scientist that led to him to be a successful serial entrepreneur, including his most recent biopharma venture — Celularity Therapeutics.

  • A Second Career As A Biotech CEO
    A Second Career As A Biotech CEO

    “This was a real turnaround type of challenge, and I knew it was going to be a steep learning curve for me,” says Steven Yatomi-Clarke of Prescient Therapeutics. “In fact, at the time, I probably underestimated the amount of work it was going to take to get the company up to scratch.”

  • Increasing Diversity Among Leadership And Boards
    Increasing Diversity Among Leadership And Boards

    Biopharmaceutical executives Ron Cohen, Acorda Therapeutics; John Maraganore, Alnylam; and Helen Torley, Halozyme Therapeutics, discuss BIO’s approach toward increasing diversity among the industry’s leadership.

  • Ending Generic Drug Shortages At Hospitals: A Capitalist Goes Nonprofit
    Ending Generic Drug Shortages At Hospitals: A Capitalist Goes Nonprofit

    The nonprofit CivicaRX continues to gain momentum, and the company’s president and CEO, Martin Van Trieste, believes it’s a business model that is “pro-competition,” and one that others throughout the biopharma industry can adapt as well.

  • Bassil Dahiyat’s Two-Decade Biotech Startup Odyssey
    Bassil Dahiyat’s Two-Decade Biotech Startup Odyssey

    Xencor’s story seems riddled with more than your average share of challenges, hurdles, and outright roadblocks. But it’s the outcome of that story — a growing company now valued at roughly $1.8 billion with nine drugs in the clinic and 150 employees — that truly make’s Xencor’s journey so compelling.

  • Developing Cannabinoid Pharmaceuticals Amid The “Cannabusiness” Craze
    Developing Cannabinoid Pharmaceuticals Amid The “Cannabusiness” Craze

    A lot of Big Pharma companies were on the sidelines because they were unclear how cannabinoid therapeutics would be regulated by the FDA,” explains Alex Wasyl, CEO of Nexien BioPharma.

  • Should Pharma Care About Digital Therapeutics?
    Should Pharma Care About Digital Therapeutics?

    So, why should pharma care about digital therapeutics? This was just one of the questions posed to a panel of digital therapeutics experts during the 2018 CNS Summit.

  • The Whirlwind Rise Of Orchard Therapeutics
    The Whirlwind Rise Of Orchard Therapeutics

    While some might think Orchard’s whirlwind rise to be a bit of luck and good timing, the reality is it involved an extremely well-executed plan — and maybe a small dose of good fortune.

  • GlycoMimetics Aiming At Tough Targets
    GlycoMimetics Aiming At Tough Targets

    An exclusive interview with Rachel King, a business person dedicated to a science-driven sector, who is CEO of GlycoMimetics, an oncology-focused biotechnology company.

  • Regeneron Manages Clinical Costs In A Fast-Growing Organization
    Regeneron Manages Clinical Costs In A Fast-Growing Organization

    Bari Kowal, VP and head of global clinical operations at Regeneron, says sponsors and CROs must partner to make clinical trial execution more efficient and cost-effective.

  • The Impact Of A Biotech CEO On Company Growth
    The Impact Of A Biotech CEO On Company Growth

    An inside look at how CEO Yuval Cohen communicates and interacts with employees at Corbus Pharmaceuticals, and how all of that affects the company’s culture.

  • Medicines360 On A Mission For Women
    Medicines360 On A Mission For Women

    Medicines360 is using all its developed-world revenue to extend access to essential medicines to all women, regardless of the economic and healthcare circumstances in their part of the world.

More executive interviews

BEYOND THE PRINTED PAGE

More From Beyond The Printed Page

LIFE SCIENCE LEADER BLOGS

  • Think You Know About Extreme Teaming?
    Think You Know About Extreme Teaming?

    Rob Wright digs into the “extreme teaming” work of Amy Edmondson, Novartis professor of leadership and management at Harvard, and Jean-Francois Harvey, assistant professor at HEC Montreal, drawing on the 2010 Chilean mining disaster as an example.

  • Do You (As A Leader) Create Great Choices?
    Do You (As A Leader) Create Great Choices?

    Rob Wright highlights the “integrative thinking” work of Jennifer Riel and Roger Martin, professors at the Rotman School of Management, University of Toronto, in helping leaders make great choices, drawing on LEGO’s entry into feature films as an example.

More From Life Science Leader Blogs

@LIFESCILEADER1